Vertex Pharmaceuticals (VRTX) reached $470.1 at the closing of the latest trading day, reflecting a -1.17% change compared to ...

Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Global Equity Strategy” ...

Fintel reports that on January 28, 2026, Barclays upgraded their outlook for Vertex Pharmaceuticals (NasdaqGS:VRTX) from ...

Vertex Pharmaceuticals (VRTX) has been in focus after a series of analyst upgrades related to its cystic fibrosis franchise ...

ClearBridge Investments, an investment management company, released its “ClearBridge All Cap Growth Strategy” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the ...

Vertex Pharmaceutical (VRTX) stock gains as RBC Capital Markets upgrades the company to Outperform, citing a durable cystic ...

A month has gone by since the last earnings report for Vertex Pharmaceuticals (VRTX). Shares have added about 6.9% in that time frame, outperforming the S&P 500. But investors have to be wondering, ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $508.25, ...

Loomis Sayles, an investment management company, released its “Growth Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the second quarter, the fund returned ...

Vertex Pharmaceuticals Incorporated’s VRTX third-quarter 2025 results were strong as it beat estimates for both earnings and sales. The company’s total revenues of $3.08 billion rose 11% year over ...

Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) shares are trending on Thursday. Shares of the Massachusetts-based biotech company, which gained 4.31% during Wednesday's regular session, tapered down 0.21% ...